Prelude Capital Management’s AstraZeneca AZN Stock Holding History

Prelude Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-600	Closed	-$41K	–	1613
2017 Q2	$41K	Buy	+600	New	+$39.2K	﹤0.01%	1060

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prelude Capital Management's AZN Position: Q2 2026 in Review

Prelude Capital Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 7,160 shares — an estimated $1.39M sold.

Prelude Capital Management first reported a position in AZN in Q2 2014 and held it in 20 quarters. The position peaked at $1.4M in Q2 2022. 1,508 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Prelude Capital Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 7,160 AstraZeneca shares in Q2 2026, an estimated $1.39M.
Prelude Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 20 quarters.
Prelude Capital Management's AstraZeneca position peaked at $1.4M in Q2 2022.
1,508 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.